venBio’s $550 Million Closing of VenBio Fund IV

Sidley Austin LLP represented venBio on the deal.

venBio announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad range of institutional investors comprising corporate pensions, financial institutions, university endowments and foundations, family offices and funds-of-funds.

Led by Managing Partners Corey Goodman, Ph.D., Robert Adelman, M.D., Aaron Royston, M.D., and Richard Gaster, M.D., Ph.D., venBio Fund IV will continue to invest primarily in therapeutics companies that are developing biopharmaceuticals for unmet medical needs. The venBio team takes an active role with each of their portfolio companies, providing strategic guidance on a range of business activities including intellectual property, chemistry, manufacturing and controls (CMC), as well as assisting with clinical trials: from trial design to endpoints to regulatory deliberations.

Sidley Austin LLP served as legal adviser to venBio with a team led by Mehdi Khodadad (Picture) and David Tang.


Involved fees earner: Mehdi Khodadad – Sidley Austin LLP; David Tang – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: venBio;

Author: Martina Bellini